Our R&D portfolio for cutaneous leishmaniasis
What we have achieved
Through collaborations with the pharmaceutical industry, biotechnology companies, academia, and other product development partnerships, we have identified several promising compounds that are now in different stages of development. In addition, our support for regional disease research platforms is helping to build and consolidate research capacity in endemic countries.
What we are doing for people living with cutaneous leishmaniasis
Our goal is to deliver short, safe, non-invasive, efficacious, affordable, and field-friendly treatments for all forms of cutaneous leishmaniasis, including topical, oral, and immunomodulator therapies.
Building capacity, uniting expertise
Research platforms and consortiums that bring together researchers and strengthen research capacities in low- and middle-income countries are central to our virtual R&D model.
Partnering for patients
Collaboration is an essential part of how we work. We have forged a diverse range of alliances and research collaborations with over 200 partners in nearly 50 countries.
Get our latest news, personal stories, research articles, and job opportunities.